Project: Anti B-Cell 2-specific Antibody for the treatment of chronic Lymphocytic Leukaemia
ABC2ALL consortium will develop a novel therapeutic strategy to treat B-cell chronic lymphocytic leukemia (CLL). The consortium will design, produce and validate a therapeutic bispecific monoclonal antibody (mAb) that simultaneously targets two specific receptors expressed on malignant B-cells. This will provide improved efficacy, specificity, and safety when compared to the current treatment regimens. Upon completion of the project, the product will be ready for further clinical development.
| Acronym | ABC2ALL (Reference Number: 10506) |
| Duration | 15/11/2016 - 15/11/2019 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 5 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 24304 | MabSolys SAS | Coordinator | France |
| 24305 | Absolute Antibody Ltd. | Partner | United Kingdom |
| 24306 | Biotechpharma UAB | Partner | Lithuania |
| 24307 | Academisch Medisch Centrum, Universiteit van Amsterdam | Partner | Netherlands |